6.4 Anemia, Coagulation, Sickle Cell, Lymphoma, and Leukemia

6.4 Anemia, Coagulation, Sickle Cell, Lymphoma, and Leukemia

Quick Answer: Query anemia for acuity and etiology (acute blood-loss anemia, iron deficiency, anemia of chronic disease, marrow failure). Acute blood-loss anemia can act as a CC when it is documented and treated. Pancytopenia needs an etiology. Aplastic anemia is bone-marrow failure, not a synonym for a low hemoglobin. Distinguish sickle cell trait from crisis. Lymphoma and leukemia are Major Diagnostic Category (MDC) 17 query targets when type, acuity, and remission status are incomplete.

This independent OpenExamPrep section is inpatient CDI teaching for hematologic and myeloproliferative documentation. It does not claim ACDIS approval.

Anemia is a finding until etiology and acuity are named

A hemoglobin of 6.8 g/dL is an indicator, not a complete diagnosis. Inpatient CDI asks: is the anemia acute or chronic? What is the mechanism? Is it being evaluated or treated this stay (transfusion, endoscopy, iron, marrow biopsy)? Under UHDDS, a laboratory abnormality that is not evaluated or treated may not belong on the claim.

Acute blood-loss anemia is the high-yield specification after gastrointestinal hemorrhage, trauma, intraoperative loss, or postpartum hemorrhage. When the provider documents acute blood-loss anemia and the team transfuses, scopes, or otherwise treats it, the diagnosis can function as a CC in many MS-DRG families. Confirm the current IPPS CC list rather than memorizing a static table from a slide deck. Do not assign acute blood-loss anemia from a hemoglobin drop alone. Do not use a yes/no query that introduces the diagnosis solely from a blood-bank note. Multiple-choice can offer acute blood-loss anemia, chronic anemia, acute-on-chronic anemia, or another specified anemia, plus Other, please specify.

Aplastic anemia is bone-marrow failure: hypocellular marrow and deficient production of hematopoietic lines. It is not a synonym for “severe anemia.” Indicators include pancytopenia, a low reticulocyte count, and marrow biopsy language. The provider must name aplastic anemia or the specific marrow diagnosis.

Pancytopenia (anemia plus leukopenia plus thrombocytopenia) is a laboratory pattern with many etiologies: chemotherapy, sepsis, hypersplenism, vitamin B12 or folate deficiency, myelodysplasia, aplastic anemia, virus. Query pancytopenia for etiology when treatment and prognosis depend on it and the cause is not stated. Do not assume aplastic anemia from pancytopenia.

Coagulation disorders

Coagulopathy, thrombocytopenia, disseminated intravascular coagulation (DIC), hemophilia, and vitamin K deficiency are different diseases. “Coags are off” is not a diagnosis. Indicators include international normalized ratio, activated partial thromboplastin time, fibrinogen, D-dimer, platelet count, schistocytes, and products given (plasma, cryoprecipitate, platelets, vitamin K). If the patient is anticoagulated, distinguish therapeutic effect from a reportable hemorrhagic disorder. Postoperative bleeding plus a drop in hemoglobin may support acute blood-loss anemia without proving DIC.

Heparin-induced thrombocytopenia, immune thrombocytopenia, and chemotherapy-induced thrombocytopenia have different implications. Query with sourced indicators. CMS HAC payment categories include deep vein thrombosis / pulmonary embolism after total knee or hip replacement. That is a circulatory HAC, but the hematologic workup still lives in this chart review. Do not merge that HAC payment provision with the HAC Reduction Program’s PSI 12 (perioperative pulmonary embolism or deep vein thrombosis) even though the clinical topic overlaps. PSI 90 currently includes PSIs 03, 06, and 08–15 on the live CMS HAC Reduction Program page; PSI 08 on that page is In Hospital Fall-Associated Fracture Rate. Keep PSI talk in quality chapters; keep the documentation specificity here.

Sickle cell disease versus trait versus crisis

Sickle cell trait is a carrier state. It is usually not the reason for admission and often does not meet UHDDS as a secondary diagnosis unless it is evaluated or complicates care (for example counseling or a hematuria workup). Sickle cell disease (HbSS, HbSC, and other genotypes) is the chronic illness. A sickle cell crisis is an acute manifestation: vaso-occlusive pain crisis, acute chest syndrome, splenic sequestration, aplastic crisis, or another specified crisis.

Query when the emergency department writes “sickle cell” and the admission is clearly a pain crisis, or when “crisis” is used without specifying the type that is being treated (opioids and fluids versus exchange transfusion and antibiotics for acute chest). Do not upgrade trait to disease. Do not leave acute chest syndrome as “pneumonia” only if hematology is treating a pulmonary sickle crisis. Infection and crisis can both be present; the provider should state the relationship. Yes/no must not introduce acute chest syndrome from a nursing oxygen note alone.

Lymphoma, leukemia, and MDC 17

Major Diagnostic Category 17 groups myeloproliferative diseases and poorly differentiated neoplasms, including many leukemia and lymphoma principal diagnoses. When lymphoma or leukemia is the reason for admission—or when it is a clinically dominant secondary diagnosis—the missing details change grouping, severity, and quality risk adjustment:

• Hodgkin versus non-Hodgkin lymphoma
• Follicular versus diffuse large B-cell versus other specified types when pathology has already named them
• Nodal versus extranodal sites when that affects the assessment
• Acute versus chronic leukemia
• Lymphoid versus myeloid lineage
• In remission, not in remission, or in relapse
• Neutropenic fever as a related acute condition versus an unrelated infection

Pathology and hematology notes are indicators. When a physician pathologist or attending hematologist has already named a disease, that is provider documentation. If the pathologist states “diffuse large B-cell lymphoma” and the attending writes only “lymphoma,” a query to incorporate the specified type can substantiate an already-documented diagnosis. Yes/no can be appropriate when the diagnosis is already in the record and you are asking the attending to confirm it. Include unable to determine where the 2026 brief requires it for POA. Do not use yes/no to introduce a brand-new hematologic diagnosis from a flow-cytometry comment alone if no provider has named a disease. Multiple-choice remains the safer format when the diagnosis would be new, and it must include Other, please specify.

Chemotherapy, colony-stimulating factors, hydroxyurea, anticoagulants, and factor products are pharmacology indicators. Neutropenic precautions and transfusion thresholds are treatment indicators that help UHDDS. None of them replaces a named diagnosis of pancytopenia, aplastic anemia, crisis, lymphoma subtype, or acute blood-loss anemia.

Clinical validation still applies. A coded acute leukemia in remission that the marrow now shows in relapse needs a query. A coded aplastic anemia with a cellular marrow and recovering counts needs validation options (confirmed with support, no longer valid, alternative diagnosis, other).

Exam-style scenarios

Scenario: GI bleed and “anemia.” Hemoglobin falls from 11.2 to 6.9 g/dL. Two units of red cells are given. Esophagogastroduodenoscopy treats an ulcer. The attending writes only “anemia.” Transfusion is an indicator, not a code. Query unspecified anemia for acute blood-loss anemia versus chronic or other specified anemia. If the provider documents acute blood-loss anemia and it is treated, it can function as a CC. Do not assign aplastic anemia because the hemoglobin is low.

Scenario: pancytopenia on chemotherapy. Day eight of induction, all three lines are down. The problem list says “pancytopenia.” That pattern may be expected myelosuppression. Query only if a distinct reportable diagnosis (aplastic anemia, invasive infection, a new marrow failure syndrome) is being treated as something more than the expected count nadir. Do not manufacture aplastic anemia from the complete blood count.

Scenario: “sickle cell” in the emergency department. The patient has documented sickle cell disease and is admitted for pain with no pulmonary infiltrate. Trait is the wrong label. Crisis type still matters if acute chest, sequestration, or aplastic crisis is in the differential. If treatment is for vaso-occlusive pain crisis, ask for that specification rather than leaving “sickle cell” as a chronic-only code.

Scenario: lymphoma as “cancer.” The pathologist already signed diffuse large B-cell lymphoma. The attending admission diagnosis is “lymphoma” and the principal-diagnosis working DRG is sitting in MDC 17. A substantiating query to incorporate the specified type is appropriate. A yes/no that tries to introduce a new leukemia from an incidental flow-cytometry comment is not.

Study habits

Read the complete blood count as a set of indicators. For every low hemoglobin, ask acuity and blood loss. For every three-line drop, ask etiology. For every sickle cell word, ask trait versus disease versus crisis type. For every lymphoma or leukemia admission, ask the MDC 17 details: type, lineage, acuity, remission. Keep HAC DVT/PE after hip or knee replacement in the circulatory HAC payment-provision list, and keep PSI 12 in the Reduction Program conversation, without merging the two.